2,4-bis(methoxymethoxy)phenylboronic acid | 863578-46-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,4-bis(methoxymethoxy)phenylboronic acid
• 英文别名: [2,4-bis(methoxymethoxy)phenyl]boronic acid
• CAS: 863578-46-5
• 化学式: C₁₀H₁₅BO₆
• 分子量: 242.036
• InChiKey: RUZDOQJUBPXMBG-UHFFFAOYSA-N

物化性质

• 沸点：
  422.5±55.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.67
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  77.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,4-bis(methoxymethoxy)phenylboronic acid 在 盐酸 、 palladium 10% on activated carbon 、 水 、 sodium carbonate 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 水 为溶剂， 反应 12.75h， 生成 1,3,8-三羟基-11H-苯并呋喃并[2,3-b][1]苯并吡喃-11-酮
  参考文献：
  名称：

  Total synthesis of the pyranocoumaronochromone lupinalbin H

  摘要：

  The pyranocoumaronochromone lupinalbin H was synthesized in three major steps, which involved preparation of 2'-hydroxygenistein by the Suzuki-Miyaura reaction, followed by oxidative cyclodehydrogenation into lupinalbin A. The final step was the regiospecific introduction of the dimethylpyran moiety to ring A of lupinalbin A via an aldol-type condensation with 3-methyl-2-butenal and 6 pi-electrocyclization. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.09.042
• 作为产物：
  描述：

  1,3-双(甲氧基甲氧基)苯 在 正丁基锂 、 碘 、 silver(I) acetate 、 氯化铵 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 氯仿 为溶剂， 反应 7.0h， 生成 2,4-bis(methoxymethoxy)phenylboronic acid
  参考文献：
  名称：

  Total synthesis of the pyranocoumaronochromone lupinalbin H

  摘要：

  The pyranocoumaronochromone lupinalbin H was synthesized in three major steps, which involved preparation of 2'-hydroxygenistein by the Suzuki-Miyaura reaction, followed by oxidative cyclodehydrogenation into lupinalbin A. The final step was the regiospecific introduction of the dimethylpyran moiety to ring A of lupinalbin A via an aldol-type condensation with 3-methyl-2-butenal and 6 pi-electrocyclization. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.09.042

文献信息

• Enantioselective Total Synthesis of Natural Isoflavans: Asymmetric Transfer Hydrogenation/Deoxygenation of Isoflavanones with Dynamic Kinetic Resolution
  作者：Anton Keßberg、Tilo Lübken、Peter Metz

  DOI：10.1021/acs.orglett.8b01034

  日期：2018.5.18

  A concise and highly enantioselective synthesis of structurally diverse isoflavans from a single chromone is described. The key transformation is a single-step conversion of racemic isoflavanones into virtually enantiopure isoflavans by domino asymmetric transfer hydrogenation/deoxygenation with dynamic kinetic resolution.

  描述了从单一色酮的结构多样的异黄烷烃的简明且高度对映选择性的合成。关键的转变是通过具有动态动力学拆分的多米诺骨牌不对称转移加氢/脱氧反应，将外消旋异黄酮一步一步转化为对映体纯的异黄酮。
• Resorcinol derivatives
  申请人：Pfizer Inc.

  公开号：US06828460B2

  公开（公告）日：2004-12-07

  The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.

  本发明涉及使用某些间苯二酚衍生物作为皮肤美白剂。
• Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors
  作者：Kazutaka Ikegashira、Takahiro Oka、Shintaro Hirashima、Satoru Noji、Hiroshi Yamanaka、Yoshinori Hara、Tsuyoshi Adachi、Jun-Ichiro Tsuruha、Satoki Doi、Yasunori Hase、Toru Noguchi、Izuru Ando、Naoki Ogura、Satoru Ikeda、Hiromasa Hashimoto

  DOI：10.1021/jm0610245

  日期：2006.11.30

  We report a new series of hepatitis C virus NS5B RNA polymerase inhibitors containing a conformationally constrained tetracyclic scaffold. SAR studies led to the identification of 6,7-dihydro-5H-benzo[5,6][1,4]diazepino[7,1-a]indoles (19 and 20) bearing a basic pendent group with high biochemical and cellular potencies. These compounds displayed a very small shift in cellular potency when the replicon

  我们报告了一系列新的丙型肝炎病毒 NS5B RNA 聚合酶抑制剂，其中包含构象受限的四环支架。SAR 研究导致鉴定 6,7-二氢-5H-苯并[5,6][1,4]二氮杂[7,1-a]吲哚（19 和 20）具有高生化和细胞效力。当在人血清白蛋白存在下进行复制子测定时，这些化合物在细胞效力方面表现出非常小的变化。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。
• TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Oka Takahiro

  公开号：US20120070409A1

  公开（公告）日：2012-03-22

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其表示为以下公式[I]，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，可用作预防或治疗丙型肝炎的药物。